XML 19 R4.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenues:    
Total revenues $ 6,590 $ 6,423
Costs and expenses:    
Cost of goods sold 1,424 1,361
Research and development expenses 1,186 1,055
In-process research and development impairment 2,700 0
Acquired in-process research and development expenses 0 62
Selling, general and administrative expenses 1,083 1,055
Total costs and expenses 6,393 3,533
Income from operations 197 2,890
Interest expense (238) (257)
Other income (expense), net (111) (369)
Income (loss) before income taxes (152) 2,264
Income tax benefit (expense) 164 (542)
Net income 12 1,722
Net loss attributable to noncontrolling interest 7 7
Net income attributable to Gilead $ 19 $ 1,729
Net income per share attributable to Gilead common stockholders - basic (in dollars per share) $ 0.02 $ 1.38
Shares used in per share calculation - basic (in shares) 1,255 1,256
Net income per share attributable to Gilead common stockholders - diluted (in dollars per share) $ 0.02 $ 1.37
Shares used in per share calculation - diluted (in shares) 1,262 1,262
Product sales    
Revenues:    
Total revenues $ 6,534 $ 6,340
Royalty, contract and other revenues    
Revenues:    
Total revenues $ 56 $ 83